Anixa says Phase 1 breast cancer vaccine trial meets endpoints, Phase 2 preparations underway
ANIX•Clinical updates on breast cancer vaccine and ovarian cancer CAR-T programs
- Anixa Biosciences will present clinical updates at the Cantor Fitzgerald Global Healthcare Conference on Sept. 11, 2026.
- Final Phase 1 breast cancer vaccine results were already presented, showing the study met its main goals, supporting Phase 2 planning.
- Ovarian cancer CAR-T program lira-cel has moved to the highest dose cohort, adding lymphodepletion, with no dose-limiting toxicities reported.
- Several treated patients have remained alive beyond one year, underpinning continued development in heavily pre-treated recurrent ovarian cancer.
Related News
Paramount Skydance Corporation Announces Extension Of Expiration Dates Of Previously Announced Exchange Offers And Tender Offers
PSKY•
Nasdaq trade halt continues UCFI.O reason not available at 09:00 AM
UCFI•
